MagSense® HER2 Breast Cancer First-in-human Study Progress Update
Imagion Biosystems Limited (ASX: IBX) is pleased to provide an update on the progress of its first-in-human study for the MagSense® HER2 breast cancer imaging…
Bob Proulx Discusses Imagion's Recent Progress with Boardroom Media
Funds raised in Imagion’s recent Rights Issue will be used to fund the first-in-human trials for the Company’s MagSense technology. Listen to CEO Bob Proulx…
2019 World Molecular Imaging Conference Poster
This study is the Company's first reported results demonstrating that the anti-HER2 nanoparticles used in Imagion's Magsense™ technology, which provide…
Imagion Biosystems hits key development milestone with initiation of toxicology study
Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the commencement of a toxicology safety study of its lead…
Imagion Biosystems teams with Planet Innovation for MagSense® Instrument Development
Click to view press release on PR/Newswire MELBOURNE, Australia, Dec. 17, 2018 /PRNewswire/ -- Imagion Biosystems Limited (ASX: IBX), a company dedicated to…
MagSense® Pre-Clinical Study Presented at 2018 SABCS
On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster "Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles" at…
MagSense Technology Animation
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense®…
Perspectives on X-Ray Imaging
This article represents the viewpoint of management. When MagSense technology reaches the clinic, it will join a distinguished pantheon of time-honored cancer…
MagSense® Technology at ASCO 2018 Annual Meeting
The ASCO 2018 Annual Meeting abstract, "Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic…
MagSense Technology Leading a Broad Trend in Cancer Medicine
This article represents the viewpoint of management. MagSense® technology is taking a leading position amidst a broad trend in cancer medicine toward finding…